Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 6/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4887136 | 0.97 | BACE1 (0.43) | BACE1SYKATMMAPTL3MBTL1 | |
| SCHEMBL4897687 | 0.94 | BACE1 (0.45) | BACE1SYKATMMAPTL3MBTL1 | |
| SCHEMBL14256997 | 0.89 | BACE1 (0.46) | BACE1SYKATMMAPTCTSK | |
| SCHEMBL4896495 | 0.86 | SYK (0.48) | BACE1SYKATMMAPTL3MBTL1 | |
| SCHEMBL1554884 | 0.86 | SYK (0.48) | BACE1SYKATMMAPTL3MBTL1 | |
| SCHEMBL15003939 | 0.86 | SYK (0.51) | BACE1SYKCTSK | |
| SCHEMBL15316174 | 0.86 | SYK (0.51) | BACE1SYKCTSK | |
| SCHEMBL4896500 | 0.85 | SYK (0.47) | BACE1SYKATMMAPTL3MBTL1 | |
| SCHEMBL14990389 | 0.84 | BACE1 (0.46) | BACE1SYKATMMAPTL3MBTL1 | |
| SCHEMBL4891550 | 0.83 | SYK (0.50) | BACE1SYKATMCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064681-A1 | Therapeutic agent for treating glaucoma | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2008-03-13 | — | — | US | disclosed |
| US-20080064681-A1 | Therapeutic agent for treating glaucoma | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064681-A1 | Therapeutic agent for treating glaucoma | PDE6G, PDE3A, PDE5A | BACE1 3546/4885SYK 4481/4885ATM 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.